#5 - GlaxoSmithKline (NYSE:GSK)
GlaxoSmithKline (GSK) - Another company experimenting with a coronavirus vaccine is GlaxoSmithKline (NYSE:GSK). However, GlaxoSmithKline is not a pure play on the vaccine front, at least not for the coronavirus. The company is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) to lend its vaccine adjuvant platform technology to any company that is working on a vaccine.
An adjuvant is used to enhance or augment the effects of a vaccine by boosting the immune system. This, in turn, makes the immune system respond more vigorously to a vaccine, providing increased immunity.
Glaxo is also partnering with the Chinese biotech company Clover Pharmaceuticals to allow its adjuvant technology to be used with the company’s vaccine candidate, Trimer.
Because the company is more indirectly involved in the battle against the coronavirus, it’s stock has not seen the same benefit as other pharmaceutical stocks. Shares of GSK stock are down over 17% for the year. However, value investors should still be attracted to the company’s dividend which is up over 6% since the stock’s recent decline.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More - Current Price
- $33.96
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 3 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $43.25 (27.4% Upside)
